Want to see CH:BION full AI Analyst Report?
BION Stock Chart & Stats
CHF50.80
CHF1.30(2.56%)
At close: 4:00 PM EDT
CHF50.80
CHF1.30(2.56%)
Day’s Range― - ―
52-Week RangeCHF30.75 - CHF53.30
Previous CloseN/A
Volume116.89K
Average Volume (3M)98.23K
Market Cap
CHF2.79B
Enterprise Value-CHF387.73
Total Cash (Recent Filing)CHF3.08B
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)2.1
Beta0.93
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.4%
Share Statistics
EPS (TTM)24.50
Shares Outstanding55,149,250
10 Day Avg. Volume119,513
30 Day Avg. Volume98,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)32.10
P/FCF Ratio7.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetZero reported debt and near-parity of equity to assets provide durable financial flexibility. This conservatism lets the firm withstand biotech market shocks, fund opportunistic purchases or distributions, and reduces refinancing risk over the next several months.
Recent Positive Cash GenerationSustained positive operating and free cash flow in recent periods supports the company's ability to cover operating costs, pay distributions and opportunistically deploy capital into the portfolio, enhancing multi-month liquidity and operational resilience.
Focused, Specialized Investment MandateA concentrated, biotech-focused mandate reflects sector expertise and allows high-conviction positions. Over 2–6 months this specialization can deliver structural alpha versus broad funds by exploiting deep knowledge of clinical and regulatory catalysts.
Bears Say
Revenue And Earnings VolatilitySharp swings in revenue and reported earnings reduce predictability of returns and distributions. For an investment vehicle, volatile performance undermines near-term NAV visibility and complicates capital allocation decisions during multi-month planning horizons.
Cyclicality In Cash Flow TrajectoryA meaningful recent FCF decline and prior negative periods show cash generation can reverse across cycles. That cyclicality constrains consistent buybacks, dividends or new investments and reduces financial predictability over the medium term.
Concentration And Sector-specific RiskHigh exposure to biotech means returns hinge on binary clinical and regulatory outcomes and sector sentiment. Such concentrated sector dependence increases downside risk from single-company events and limits diversification benefits over coming months.
BB Biotech News
BION FAQ
What was BB Biotech AG’s price range in the past 12 months?
BB Biotech AG lowest stock price was CHF30.75 and its highest was CHF53.30 in the past 12 months.
What is BB Biotech AG’s market cap?
BB Biotech AG’s market cap is CHF2.79B.
When is BB Biotech AG’s upcoming earnings report date?
BB Biotech AG’s upcoming earnings report date is Oct 23, 2026 which is in 78 days.
How were BB Biotech AG’s earnings last quarter?
BB Biotech AG released its earnings results on Jul 24, 2026. The company reported CHF8.181 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is BB Biotech AG overvalued?
According to Wall Street analysts BB Biotech AG’s price is currently Overvalued.
Does BB Biotech AG pay dividends?
BB Biotech AG pays a Annually dividend of CHF2.25 which represents an annual dividend yield of 4.4%. See more information on BB Biotech AG dividends here
What is BB Biotech AG’s EPS estimate?
BB Biotech AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BB Biotech AG have?
BB Biotech AG has 55,149,250 shares outstanding.
What happened to BB Biotech AG’s price movement after its last earnings report?
BB Biotech AG reported an EPS of CHF8.181 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.804%.
Which hedge fund is a major shareholder of BB Biotech AG?
Currently, no hedge funds are holding shares in CH:BION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BB Biotech AG
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―